Zevra Therapeutics beats FY 2025 revenue expectations

Zevra Therapeutics

09/03/2026 20:20

Overview

Rare disease therapy firm's FY 2025 revenue beat analyst expectations

Net income for FY 2025 was $83.2 mln, marking a significant turnaround

Company relocated headquarters to Boston, enhancing access to specialized talent

Outlook

GLOBAL EXPANSION - Expanded Access Program and EU regulatory progress aim to broaden MIPLYFFA's reach

Result Drivers

MIPLYFFA PERFORMANCE - Strong sales of MIPLYFFA drove Q4 revenue growth, with $26.4 mln in net revenue

U.S. MARKET ACCESS - MIPLYFFA achieved 68% market access coverage in the U.S., supporting revenue growth

Cash, cash equivalents and securities were $238.9 million as of December 31, 2025

Company press release: ID:nGNXj4DS6

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Beat
$106.47 mln
$100.38 mln (8 Analysts)
FY Net Income
$83.23 mln
FY Income from Operations
-$62.94 mln
FY Operating Expenses
$90.36 mln
FY Pretax Profit
$86.68 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Zevra Therapeutics Inc is $24.00, about 167.3% above its March 6 closing price of $8.98

The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 14 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)